Solventum Corp Files 8-K for Material Agreement
Ticker: SOLV · Form: 8-K · Filed: 2025-06-25T00:00:00.000Z
Sentiment: neutral
Topics: corporate-event, filing, spin-off
Related Tickers: MMM
TL;DR
Solventum Corp (formerly 3M Health Care) filed an 8-K on 6/25/25 for a material agreement.
AI Summary
Solventum Corporation, formerly part of 3M Company, filed an 8-K on June 25, 2025, reporting a material definitive agreement and financial statements. The company was incorporated in Delaware and has its principal executive offices in Maplewood, MN.
Why It Matters
This filing indicates a significant corporate event for Solventum, potentially related to its separation from 3M or other strategic partnerships.
Risk Assessment
Risk Level: low — The filing is a standard corporate disclosure and does not inherently present immediate financial risk.
Key Numbers
- 001-41968 — SEC File Number (Identifies the company's filing with the SEC.)
- 92-2008841 — IRS Employer Identification No. (Tax identification number for the company.)
Key Players & Entities
- Solventum Corp (company) — Registrant
- 3M Company (company) — Former Parent Company
- June 25, 2025 (date) — Date of Report
- Maplewood, MN (location) — Principal Executive Offices
- 3M Health Care Co (company) — Former Company Name
FAQ
What is the nature of the material definitive agreement filed by Solventum Corp?
The filing indicates an 'Entry into a Material Definitive Agreement' but does not specify the details of the agreement within the provided text.
When was Solventum Corporation incorporated?
Solventum Corporation was incorporated in Delaware.
What was Solventum Corporation's former name?
Solventum Corporation's former name was 3M Health Care Co.
Where are Solventum Corporation's principal executive offices located?
Solventum Corporation's principal executive offices are located at 3M Center, Building 275-6W, East Maplewood, MN 55144.
What is the SIC code for Solventum Corp?
The Standard Industrial Classification (SIC) code for Solventum Corp is 3841, which corresponds to SURGICAL & MEDICAL INSTRUMENTS & APPARATUS.
From the Filing
0001964738-25-000056.txt : 20250625 0001964738-25-000056.hdr.sgml : 20250625 20250625163445 ACCESSION NUMBER: 0001964738-25-000056 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 160 CONFORMED PERIOD OF REPORT: 20250625 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250625 DATE AS OF CHANGE: 20250625 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Solventum Corp CENTRAL INDEX KEY: 0001964738 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 922008841 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41968 FILM NUMBER: 251074049 BUSINESS ADDRESS: STREET 1: C/O 3M COMPANY STREET 2: 3M CENTER, BUILDING 275-6W-02 CITY: ST. PAUL STATE: MN ZIP: 55144-1000 BUSINESS PHONE: 651-733-1110 MAIL ADDRESS: STREET 1: C/O 3M COMPANY STREET 2: 3M CENTER, BUILDING 275-6W-02 CITY: ST. PAUL STATE: MN ZIP: 55144-1000 FORMER COMPANY: FORMER CONFORMED NAME: 3M Health Care Co DATE OF NAME CHANGE: 20230203 8-K 1 solv-20250625.htm 8-K solv-20250625 FALSE 0001964738 0001964738 2025-06-25 2025-06-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 25, 2025      Solventum Corporation (Exact name of registrant as specified in its charter) Delaware 001-41968 92-2008841 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 3M Center, Building 275-6W 2510 Conway Avenue East Maplewood , MN 55144 (Address of Principal Executive Offices, including Zip code) ( 651 ) 733-1110 (Registrant’s telephone number, including area code) (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.01 per share SOLV New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 1.01 Entry into a Material Definitive Agreement. As previously disclosed, on February 25, 2025, Solventum Corporation, a Delaware corporation (“Solventum”) and Thermo Fisher Scientific Inc., a Delaware corporation (“Buyer”), entered into a Transaction Agreement (the “Initial Agreement”), pursuant to which, subject to the satisfaction or waiver of certain conditions, Buyer agreed to acquire from Solventum certain assets and liabilities related to Solventum’s purification and filtration business. On June 25, 2025, Solventum and Buyer entered into an Amended and Restated Transaction Agreement (the “Agreement”) to exclude